By Dave Sebastian

 

Eli Lilly & Co. (LLY) said it has struck an agreement with DexCom Inc. (DXCM) to use Dexcom products in Lilly's currently developed personalized diabetes management system.

Under the non-exclusive agreement, Lilly said Monday it would use Dexcom's continuous glucose monitoring devices in both the pen- and pump-based platforms of the system.

The pen-based platform aims to integrate personalized data from a prefiled, disposable insulin pen with data from glucose-sensing technologies into a compatible software application, Lilly said.

Lilly said the pump-based platform is a hybrid-closed-loop system that would automate insulin dosing by integrating an insulin pump, continuous glucose monitor and a handheld controller or smartphone application that controls the system.

Write to Dave Sebastian at dave.sebastian@wsj.com

 

(END) Dow Jones Newswires

December 16, 2019 07:12 ET (12:12 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more DexCom Charts.
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more DexCom Charts.